Literature DB >> 26761932

Status report from the American Acne & Rosacea Society on medical management of acne in adult women, part 3: oral therapies.

James Q Del Rosso1, Julie C Harper2, Emmy M Graber3, Diane Thiboutot4, Nanette B Silverberg5, Lawrence F Eichenfield6.   

Abstract

Parts 1 and 2 of this 3-part series provided an overview of the epidemiology, visible patterns, and important considerations for clinical and laboratory evaluation of acne vulgaris (AV) in adult women and reviewed the role of proper skin care and topical therapies in this patient population. In Part 3, oral therapies including combination oral contraceptives, spironolactone, antibiotics, and isotretinoin are discussed along with important considerations that clinicians should keep in mind when selecting oral agents for management of AV in adult women.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26761932

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  3 in total

1.  Status Report from the Scientific Panel on Antibiotic Use in Dermatology of the American Acne and Rosacea Society: Part 3: Current Perspectives on Skin and Soft Tissue Infections with Emphasis on Methicillin-resistant Staphylococcus aureus, Commonly Encountered Scenarios when Antibiotic Use May Not Be Needed, and Concluding Remarks on Rational Use of Antibiotics in Dermatology.

Authors:  James Q Del Rosso; Ted Rosen; Diane Thiboutot; Guy F Webster; Richard L Gallo; James J Leyden; Clay Walker; George Zhanel; Lawrence Eichenfield
Journal:  J Clin Aesthet Dermatol       Date:  2016-06-01

2.  Adult Acne Versus Adolescent Acne: A Retrospective Study of 1,167 Patients.

Authors:  Nevena Skroza; Ersilia Tolino; Alessandra Mambrin; Sara Zuber; Veronica Balduzzi; Anna Marchesiello; Nicoletta Bernardini; Ilaria Proietti; Concetta Potenza
Journal:  J Clin Aesthet Dermatol       Date:  2018-01-01

3.  Eligibility Criteria Related to Hormone Therapy in Acne Clinical Trials: A Systematic Review.

Authors:  Taryn M DeGrazia; Robin Rolader; Diane M Thiboutot; Howa Yeung
Journal:  J Invest Dermatol       Date:  2020-05-26       Impact factor: 8.551

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.